(Q39758059)

English

Interruption of nonnucleoside reverse transcriptase inhibitor (NNRTI) therapy for 2 months has no effect on levels of human immunodeficiency virus type 1 in plasma of patients harboring viruses with mutations associated with resistance to NNRTIs

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

14 September 2017

Interruption of nonnucleoside reverse transcriptase inhibitor (NNRTI) therapy for 2 months has no effect on levels of human immunodeficiency virus type 1 in plasma of patients harboring viruses with mutations associated with resistance to NNRTIs (English)

1 reference

Europe PubMed Central

PMC publication ID

14 September 2017

Christine Katlama

11

object named as

Christine Katlama

0 references

Gilles Peytavin

10

object named as

Gilles Peytavin

1 reference

Europe PubMed Central

PMC publication ID

14 September 2017

2

object named as

Anne Simon

1 reference

Europe PubMed Central

PMC publication ID

14 September 2017

Anne-Geneviève Marcelin

6

object named as

Anne Genevieve Marcelin

1 reference

Europe PubMed Central

PMC publication ID

14 September 2017

Constance Delaugerre

7

object named as

Constance Delaugerre

1 reference

Europe PubMed Central

PMC publication ID

14 September 2017

1

object named as

Marc Wirden

1 reference

Europe PubMed Central

PMC publication ID

14 September 2017

4

object named as

Roland Tubiana

1 reference

Europe PubMed Central

PMC publication ID

14 September 2017

Luminita Schneider

3

object named as

Luminita Schneider

1 reference

Europe PubMed Central

PMC publication ID

14 September 2017

Mayeule Legrand

8

object named as

Mayeule Legrand

1 reference

Europe PubMed Central

PMC publication ID

14 September 2017

author name string

Luc Paris

5

1 reference

Europe PubMed Central

PMC publication ID

14 September 2017

Serge Herson

9

1 reference

Europe PubMed Central

PMC publication ID

14 September 2017

Vincent Calvez

12

1 reference

Europe PubMed Central

PMC publication ID

14 September 2017

language of work or name

0 references

publication date

1 June 2003

1 reference

Europe PubMed Central

PMC publication ID

14 September 2017

Journal of Clinical Microbiology

1 reference

Europe PubMed Central

PMC publication ID

14 September 2017

41

1 reference

Europe PubMed Central

PMC publication ID

14 September 2017

6

1 reference

Europe PubMed Central

PMC publication ID

14 September 2017

2713-2715

1 reference

Europe PubMed Central

PMC publication ID

14 September 2017

Genotypic correlates of phenotypic resistance to efavirenz in virus isolates from patients failing nonnucleoside reverse transcriptase inhibitor therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=156544

22 September 2017

International perspectives on antiretroviral resistance. Nonnucleoside reverse transcriptase inhibitor resistance

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=156544

22 September 2017

Mutants of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase resistant to nonnucleoside reverse transcriptase inhibitors demonstrate altered rates of RNase H cleavage that correlate with HIV-1 replication fitness in cell culture

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=156544

22 September 2017

Human immunodeficiency virus type 1 mutations selected in patients failing efavirenz combination therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=156544

22 September 2017

Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=156544

22 September 2017

Human immunodeficiency virus type 1 mutants resistant to nonnucleoside inhibitors of reverse transcriptase arise in tissue culture

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=156544

22 September 2017

In vitro selection and molecular characterization of human immunodeficiency virus-1 resistant to non-nucleoside inhibitors of reverse transcriptase

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=156544

22 September 2017

High-dose nevirapine: safety, pharmacokinetics, and antiviral effect in patients with human immunodeficiency virus infection

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=156544

17 June 2018

Resistance profile and cross-resistance of HIV-1 among patients failing a non-nucleoside reverse transcriptase inhibitor-containing regimen

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=156544

20 August 2018

The role of genotypic resistance testing in selecting therapy for HIV

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=156544

20 August 2018

Determination of twelve antiretroviral agents in human plasma sample using reversed-phase high-performance liquid chromatography.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=156544

20 August 2018

Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an International AIDS Society-USA Panel.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=156544

20 August 2018

Non-nucleoside reverse transcriptase inhibitor resistance among patients failing a nevirapine plus protease inhibitor-containing regimen.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=156544

20 August 2018

Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=156544

20 August 2018

A Pilot Study to Evaluate the Development of Resistance to Nevirapine in Asymptomatic Human Immunodeficiency Virus-Infected Patients with CD4 Cell Counts of >500/mm3 : AIDS Clinical Trials Group Protocol 208

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=156544

20 August 2018

Identifiers

10.1128/JCM.41.6.2713-2715.2003

1 reference

Europe PubMed Central

PMC publication ID

14 September 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

14 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

14 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39758059&oldid=2089999092"